COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2024. For the period, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03.